Skip to Content
menu

Change Life Stories

Shanna Living with Hereditary Angioedema Type 1

There’s so much uncertainty with rare disease — the best treatment is your own confidence in making the decisions that are right for you.

Read Shanna's story

Change Life Stories

Nancy Living with ATTR Amyloidosis with Polyneuropathy

I look at my dad and think, ‘Is that what’s going to happen to me in the future?’

Read Nancy's story

Change Life Stories

Milton Living with ATTR Amyloidosis with Cardiomyopathy

When I think about memories, I smile. My memories keep me going.

Read Milton's story

News Updates

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Read more

Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Read more
View all news updates

Aiming to make the impossible, possible

Our
Mission

Transforming lives of people with severe diseases by developing potentially curative genome editing treatments.

Learn more

Programs
and Pipeline

Each one of us together for patients

Learn more

Full-Spectrum Approach

Opening a new era in medicine

Learn more

Join Us

See how you can change life stories with genome editing.

Learn more